nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—CYP1A2—Clobetasol propionate—psoriasis	0.197	0.656	CbGbCtD
Rasagiline—CYP1A2—Methoxsalen—psoriasis	0.104	0.344	CbGbCtD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—S100A7—psoriasis	0.00901	0.0626	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—IL23A—psoriasis	0.00464	0.0322	CbGpPWpGaD
Rasagiline—BCL2—Tretinoin—Acitretin—psoriasis	0.00429	0.333	CbGdCrCtD
Rasagiline—BCL2—Isotretinoin—Acitretin—psoriasis	0.00429	0.333	CbGdCrCtD
Rasagiline—BCL2—Alitretinoin—Acitretin—psoriasis	0.00429	0.333	CbGdCrCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—IVL—psoriasis	0.00429	0.0298	CbGpPWpGaD
Rasagiline—MAOB—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00428	0.0298	CbGpPWpGaD
Rasagiline—BCL2—Overview of nanoparticle effects—CRP—psoriasis	0.00307	0.0213	CbGpPWpGaD
Rasagiline—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.00294	0.0205	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.00292	0.0203	CbGpPWpGaD
Rasagiline—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—TNFAIP3—psoriasis	0.00268	0.0186	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—IL4—psoriasis	0.00247	0.0171	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—CYP2S1—psoriasis	0.00227	0.0158	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—CAT—psoriasis	0.00222	0.0154	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	0.00204	0.0142	CbGpPWpGaD
Rasagiline—BCL2—Overview of nanoparticle effects—CXCL8—psoriasis	0.002	0.0139	CbGpPWpGaD
Rasagiline—MAOB—Tryptophan metabolism—CAT—psoriasis	0.00196	0.0136	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.00186	0.0129	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—SOCS1—psoriasis	0.00185	0.0128	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNFRSF1B—psoriasis	0.00184	0.0128	CbGpPWpGaD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—NFKBIA—psoriasis	0.0018	0.0125	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—SOCS1—psoriasis	0.00177	0.0123	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TNFRSF1B—psoriasis	0.00172	0.012	CbGpPWpGaD
Rasagiline—BCL2—Inflammasomes—NFKB1—psoriasis	0.00172	0.0119	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—SOCS1—psoriasis	0.00165	0.0114	CbGpPWpGaD
Rasagiline—BCL2—Estrogen signaling pathway—JUN—psoriasis	0.00159	0.0111	CbGpPWpGaD
Rasagiline—BCL2—Estrogen signaling pathway—NFKB1—psoriasis	0.00153	0.0107	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—ICAM1—psoriasis	0.00144	0.01	CbGpPWpGaD
Rasagiline—BCL2—Overview of nanoparticle effects—TNF—psoriasis	0.00139	0.00966	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—NFKBIA—psoriasis	0.00133	0.00928	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.00129	0.00897	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—CARM1—psoriasis	0.00127	0.00885	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—TGFA—psoriasis	0.00127	0.00885	CbGpPWpGaD
Rasagiline—BCL2—TP53 Network—TP53—psoriasis	0.00123	0.00852	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00122	0.0085	CbGpPWpGaD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00121	0.00839	CbGpPWpGaD
Rasagiline—BCL2—EPO signaling pathway—NFKB1—psoriasis	0.00118	0.00819	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—TYK2—psoriasis	0.00117	0.00814	CbGpPWpGaD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—NFKB1—psoriasis	0.00115	0.00799	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—NOS2—psoriasis	0.00113	0.00786	CbGpPWpGaD
Rasagiline—BCL2—Overview of nanoparticle effects—IL6—psoriasis	0.00112	0.0078	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—ITGAL—psoriasis	0.00108	0.00752	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.00108	0.00752	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—NFKB1—psoriasis	0.00105	0.00729	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—JUN—psoriasis	0.00102	0.00712	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000991	0.00689	CbGpPWpGaD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—JUN—psoriasis	0.000984	0.00684	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—JUN—psoriasis	0.000984	0.00684	CbGpPWpGaD
Rasagiline—BCL2—Activation of BH3-only proteins—TP53—psoriasis	0.000984	0.00684	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CAT—psoriasis	0.000956	0.00665	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—CXCL8—psoriasis	0.000936	0.00651	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—IFNG—psoriasis	0.000931	0.00647	CbGpPWpGaD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—psoriasis	0.000894	0.00621	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—STAT3—psoriasis	0.000885	0.00615	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—JUN—psoriasis	0.00087	0.00605	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—IFNG—psoriasis	0.000868	0.00603	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—NFKBIA—psoriasis	0.000853	0.00593	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—NFKB1—psoriasis	0.000851	0.00592	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—STAT3—psoriasis	0.000851	0.00592	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—PCNA—psoriasis	0.000849	0.0059	CbGpPWpGaD
Rasagiline—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NFKB1—psoriasis	0.000824	0.00573	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—STAT3—psoriasis	0.00082	0.0057	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—CXCL8—psoriasis	0.000807	0.00561	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—JUN—psoriasis	0.000805	0.0056	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—NFKBIA—psoriasis	0.0008	0.00556	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TNF—psoriasis	0.000798	0.00555	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—NFKBIA—psoriasis	0.000793	0.00551	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—VDR—psoriasis	0.00076	0.00528	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KIR2DS1—psoriasis	0.000759	0.00527	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—STAT3—psoriasis	0.000753	0.00523	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—JUN—psoriasis	0.00075	0.00521	CbGpPWpGaD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—TNF—psoriasis	0.000737	0.00512	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—STAT3—psoriasis	0.000729	0.00507	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—TP53—psoriasis	0.000704	0.00489	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TP53—psoriasis	0.000704	0.00489	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—STAT3—psoriasis	0.000696	0.00484	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—PCNA—psoriasis	0.000674	0.00469	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—TNF—psoriasis	0.000662	0.0046	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—STAT3—psoriasis	0.000649	0.00451	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CD4—psoriasis	0.000632	0.00439	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—TP53—psoriasis	0.000626	0.00435	CbGpPWpGaD
Rasagiline—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000599	0.00417	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—DDX58—psoriasis	0.000587	0.00408	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000587	0.00408	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—TNF—psoriasis	0.000577	0.00401	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CXCL8—psoriasis	0.000565	0.00393	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—JUN—psoriasis	0.000565	0.00393	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000562	0.0039	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IFNG—psoriasis	0.000547	0.0038	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—NFKB1—psoriasis	0.000544	0.00378	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—JUN—psoriasis	0.00053	0.00369	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000526	0.00366	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000526	0.00366	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000519	0.00361	CbGpPWpGaD
Rasagiline—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000518	0.0036	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—NFKB1—psoriasis	0.00051	0.00355	CbGpPWpGaD
Rasagiline—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.00051	0.00355	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CXCL8—psoriasis	0.000509	0.00354	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—NFKB1—psoriasis	0.000506	0.00352	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—JUN—psoriasis	0.000473	0.00329	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—JUN—psoriasis	0.000459	0.00319	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NDUFA5—psoriasis	0.000458	0.00318	CbGpPWpGaD
Rasagiline—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000454	0.00316	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—IL6—psoriasis	0.000453	0.00315	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000442	0.00307	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—NFKB1—psoriasis	0.000442	0.00307	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNF—psoriasis	0.000423	0.00294	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IFIH1—psoriasis	0.000404	0.00281	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000391	0.00272	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP2S1—psoriasis	0.000389	0.0027	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERAP1—psoriasis	0.000388	0.0027	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HLA-C—psoriasis	0.000383	0.00266	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—TNFAIP3—psoriasis	0.000378	0.00263	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—JUN—psoriasis	0.000376	0.00261	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—psoriasis	0.000373	0.00259	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—JUN—psoriasis	0.000354	0.00246	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—psoriasis	0.00035	0.00243	CbGpPWpGaD
Rasagiline—BCL2—Immune System—DDX58—psoriasis	0.000342	0.00238	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—NFKB1—psoriasis	0.00034	0.00237	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HLA-E—psoriasis	0.000318	0.00221	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—psoriasis	0.000312	0.00217	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—VEGFA—psoriasis	0.000309	0.00215	CbGpPWpGaD
Rasagiline—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	0.000304	0.00211	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—psoriasis	0.000303	0.00211	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—JUN—psoriasis	0.000294	0.00205	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.000293	0.00204	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL6—psoriasis	0.000286	0.00199	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	0.000282	0.00196	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—SOCS1—psoriasis	0.000265	0.00185	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNF—psoriasis	0.000259	0.0018	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ITGAL—psoriasis	0.000259	0.0018	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—VEGFA—psoriasis	0.000257	0.00179	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	0.000256	0.00178	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000252	0.00175	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—TP53—psoriasis	0.000248	0.00172	CbGpPWpGaD
Rasagiline—BCL2—Immune System—REL—psoriasis	0.000242	0.00168	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFIH1—psoriasis	0.000235	0.00164	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—psoriasis	0.000233	0.00162	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—psoriasis	0.000229	0.00159	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HLA-B—psoriasis	0.000226	0.00157	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HLA-C—psoriasis	0.000223	0.00155	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TNFAIP3—psoriasis	0.00022	0.00153	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	0.000219	0.00153	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000218	0.00152	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.00021	0.00146	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CRP—psoriasis	0.0002	0.00139	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	0.000193	0.00134	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.00019	0.00132	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CARM1—psoriasis	0.00019	0.00132	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HLA-E—psoriasis	0.000185	0.00129	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—NFKBIA—psoriasis	0.000183	0.00127	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.000163	0.00113	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	0.000163	0.00113	CbGpPWpGaD
Rasagiline—BCL2—Immune System—SOCS1—psoriasis	0.000155	0.00107	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—TYK2—psoriasis	0.000149	0.00104	CbGpPWpGaD
Rasagiline—Hypotension—Hydrocortisone—psoriasis	0.000144	0.000265	CcSEcCtD
Rasagiline—Haematuria—Methotrexate—psoriasis	0.000143	0.000264	CcSEcCtD
Rasagiline—Feeling abnormal—Cyclosporine—psoriasis	0.000143	0.000263	CcSEcCtD
Rasagiline—Shock—Triamcinolone—psoriasis	0.000143	0.000263	CcSEcCtD
Rasagiline—Insomnia—Prednisolone—psoriasis	0.000143	0.000263	CcSEcCtD
Rasagiline—Alopecia—Prednisone—psoriasis	0.000142	0.000262	CcSEcCtD
Rasagiline—Gastrointestinal pain—Cyclosporine—psoriasis	0.000142	0.000261	CcSEcCtD
Rasagiline—Loss of consciousness—Dexamethasone—psoriasis	0.000142	0.000261	CcSEcCtD
Rasagiline—Loss of consciousness—Betamethasone—psoriasis	0.000142	0.000261	CcSEcCtD
Rasagiline—Dizziness—Mycophenolic acid—psoriasis	0.000142	0.000261	CcSEcCtD
Rasagiline—Epistaxis—Methotrexate—psoriasis	0.000142	0.000261	CcSEcCtD
Rasagiline—Paraesthesia—Prednisolone—psoriasis	0.000142	0.000261	CcSEcCtD
Rasagiline—Mental disorder—Prednisone—psoriasis	0.000141	0.00026	CcSEcCtD
Rasagiline—Malnutrition—Prednisone—psoriasis	0.00014	0.000259	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.00014	0.000258	CcSEcCtD
Rasagiline—Hyperhidrosis—Triamcinolone—psoriasis	0.00014	0.000258	CcSEcCtD
Rasagiline—Convulsion—Betamethasone—psoriasis	0.00014	0.000257	CcSEcCtD
Rasagiline—Convulsion—Dexamethasone—psoriasis	0.00014	0.000257	CcSEcCtD
Rasagiline—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000139	0.000257	CcSEcCtD
Rasagiline—Insomnia—Hydrocortisone—psoriasis	0.000139	0.000257	CcSEcCtD
Rasagiline—Hypertension—Dexamethasone—psoriasis	0.000139	0.000256	CcSEcCtD
Rasagiline—Hypertension—Betamethasone—psoriasis	0.000139	0.000256	CcSEcCtD
Rasagiline—Paraesthesia—Hydrocortisone—psoriasis	0.000138	0.000255	CcSEcCtD
Rasagiline—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000138	0.000255	CcSEcCtD
Rasagiline—Urticaria—Cyclosporine—psoriasis	0.000138	0.000254	CcSEcCtD
Rasagiline—BCL2—Immune System—CD8A—psoriasis	0.000137	0.000953	CbGpPWpGaD
Rasagiline—Body temperature increased—Cyclosporine—psoriasis	0.000137	0.000252	CcSEcCtD
Rasagiline—Abdominal pain—Cyclosporine—psoriasis	0.000137	0.000252	CcSEcCtD
Rasagiline—Anxiety—Dexamethasone—psoriasis	0.000137	0.000252	CcSEcCtD
Rasagiline—Anxiety—Betamethasone—psoriasis	0.000137	0.000252	CcSEcCtD
Rasagiline—Vomiting—Mycophenolic acid—psoriasis	0.000136	0.000251	CcSEcCtD
Rasagiline—Discomfort—Betamethasone—psoriasis	0.000136	0.00025	CcSEcCtD
Rasagiline—Discomfort—Dexamethasone—psoriasis	0.000136	0.00025	CcSEcCtD
Rasagiline—Dyspepsia—Hydrocortisone—psoriasis	0.000135	0.00025	CcSEcCtD
Rasagiline—Haemoglobin—Methotrexate—psoriasis	0.000135	0.000249	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CD4—psoriasis	0.000135	0.00094	CbGpPWpGaD
Rasagiline—Rash—Mycophenolic acid—psoriasis	0.000135	0.000249	CcSEcCtD
Rasagiline—Dermatitis—Mycophenolic acid—psoriasis	0.000135	0.000248	CcSEcCtD
Rasagiline—Haemorrhage—Methotrexate—psoriasis	0.000135	0.000248	CcSEcCtD
Rasagiline—Urticaria—Mycophenolate mofetil—psoriasis	0.000134	0.000247	CcSEcCtD
Rasagiline—Headache—Mycophenolic acid—psoriasis	0.000134	0.000247	CcSEcCtD
Rasagiline—Decreased appetite—Hydrocortisone—psoriasis	0.000134	0.000247	CcSEcCtD
Rasagiline—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000134	0.000246	CcSEcCtD
Rasagiline—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000134	0.000246	CcSEcCtD
Rasagiline—Urinary tract disorder—Methotrexate—psoriasis	0.000133	0.000245	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000133	0.000245	CcSEcCtD
Rasagiline—Urethral disorder—Methotrexate—psoriasis	0.000132	0.000243	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000132	0.000243	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-B—psoriasis	0.000132	0.000917	CbGpPWpGaD
Rasagiline—Insomnia—Triamcinolone—psoriasis	0.000131	0.000242	CcSEcCtD
Rasagiline—Infection—Betamethasone—psoriasis	0.000131	0.000241	CcSEcCtD
Rasagiline—Infection—Dexamethasone—psoriasis	0.000131	0.000241	CcSEcCtD
Rasagiline—Ill-defined disorder—Prednisone—psoriasis	0.00013	0.00024	CcSEcCtD
Rasagiline—Paraesthesia—Triamcinolone—psoriasis	0.00013	0.00024	CcSEcCtD
Rasagiline—Feeling abnormal—Prednisolone—psoriasis	0.00013	0.000239	CcSEcCtD
Rasagiline—Anaemia—Prednisone—psoriasis	0.00013	0.000239	CcSEcCtD
Rasagiline—Shock—Betamethasone—psoriasis	0.000129	0.000238	CcSEcCtD
Rasagiline—Shock—Dexamethasone—psoriasis	0.000129	0.000238	CcSEcCtD
Rasagiline—Dyspnoea—Triamcinolone—psoriasis	0.000129	0.000238	CcSEcCtD
Rasagiline—Nervous system disorder—Betamethasone—psoriasis	0.000129	0.000238	CcSEcCtD
Rasagiline—Nervous system disorder—Dexamethasone—psoriasis	0.000129	0.000238	CcSEcCtD
Rasagiline—Agitation—Prednisone—psoriasis	0.000129	0.000238	CcSEcCtD
Rasagiline—Hypersensitivity—Cyclosporine—psoriasis	0.000128	0.000235	CcSEcCtD
Rasagiline—Dyspepsia—Triamcinolone—psoriasis	0.000128	0.000235	CcSEcCtD
Rasagiline—Nausea—Mycophenolic acid—psoriasis	0.000127	0.000234	CcSEcCtD
Rasagiline—Hyperhidrosis—Betamethasone—psoriasis	0.000127	0.000234	CcSEcCtD
Rasagiline—Hyperhidrosis—Dexamethasone—psoriasis	0.000127	0.000234	CcSEcCtD
Rasagiline—Feeling abnormal—Hydrocortisone—psoriasis	0.000127	0.000234	CcSEcCtD
Rasagiline—Malaise—Prednisone—psoriasis	0.000127	0.000233	CcSEcCtD
Rasagiline—Vertigo—Prednisone—psoriasis	0.000126	0.000232	CcSEcCtD
Rasagiline—Eye disorder—Methotrexate—psoriasis	0.000126	0.000232	CcSEcCtD
Rasagiline—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000126	0.000232	CcSEcCtD
Rasagiline—Syncope—Prednisone—psoriasis	0.000126	0.000232	CcSEcCtD
Rasagiline—Anorexia—Dexamethasone—psoriasis	0.000125	0.000231	CcSEcCtD
Rasagiline—Anorexia—Betamethasone—psoriasis	0.000125	0.000231	CcSEcCtD
Rasagiline—Urticaria—Prednisolone—psoriasis	0.000125	0.000231	CcSEcCtD
Rasagiline—Cardiac disorder—Methotrexate—psoriasis	0.000125	0.00023	CcSEcCtD
Rasagiline—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000124	0.000229	CcSEcCtD
Rasagiline—Asthenia—Cyclosporine—psoriasis	0.000124	0.000229	CcSEcCtD
Rasagiline—Loss of consciousness—Prednisone—psoriasis	0.000123	0.000227	CcSEcCtD
Rasagiline—Hypotension—Betamethasone—psoriasis	0.000123	0.000226	CcSEcCtD
Rasagiline—Hypotension—Dexamethasone—psoriasis	0.000123	0.000226	CcSEcCtD
Rasagiline—Pruritus—Cyclosporine—psoriasis	0.000123	0.000226	CcSEcCtD
Rasagiline—Urticaria—Hydrocortisone—psoriasis	0.000122	0.000225	CcSEcCtD
Rasagiline—Angiopathy—Methotrexate—psoriasis	0.000122	0.000225	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-A—psoriasis	0.000122	0.000849	CbGpPWpGaD
Rasagiline—Immune system disorder—Methotrexate—psoriasis	0.000122	0.000224	CcSEcCtD
Rasagiline—Abdominal pain—Hydrocortisone—psoriasis	0.000122	0.000224	CcSEcCtD
Rasagiline—Body temperature increased—Hydrocortisone—psoriasis	0.000122	0.000224	CcSEcCtD
Rasagiline—Convulsion—Prednisone—psoriasis	0.000122	0.000224	CcSEcCtD
Rasagiline—Mediastinal disorder—Methotrexate—psoriasis	0.000121	0.000224	CcSEcCtD
Rasagiline—Asthenia—Mycophenolate mofetil—psoriasis	0.000121	0.000223	CcSEcCtD
Rasagiline—Hypertension—Prednisone—psoriasis	0.000121	0.000223	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—JUN—psoriasis	0.000121	0.000841	CbGpPWpGaD
Rasagiline—Chills—Methotrexate—psoriasis	0.000121	0.000223	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.00012	0.000221	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Betamethasone—psoriasis	0.00012	0.000221	CcSEcCtD
Rasagiline—Pruritus—Mycophenolate mofetil—psoriasis	0.00012	0.00022	CcSEcCtD
Rasagiline—Arthralgia—Prednisone—psoriasis	0.000119	0.00022	CcSEcCtD
Rasagiline—Feeling abnormal—Triamcinolone—psoriasis	0.000119	0.00022	CcSEcCtD
Rasagiline—Anxiety—Prednisone—psoriasis	0.000119	0.000219	CcSEcCtD
Rasagiline—Alopecia—Methotrexate—psoriasis	0.000119	0.000219	CcSEcCtD
Rasagiline—Insomnia—Dexamethasone—psoriasis	0.000119	0.000219	CcSEcCtD
Rasagiline—Insomnia—Betamethasone—psoriasis	0.000119	0.000219	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000119	0.000219	CcSEcCtD
Rasagiline—Diarrhoea—Cyclosporine—psoriasis	0.000118	0.000218	CcSEcCtD
Rasagiline—Paraesthesia—Dexamethasone—psoriasis	0.000118	0.000218	CcSEcCtD
Rasagiline—Paraesthesia—Betamethasone—psoriasis	0.000118	0.000218	CcSEcCtD
Rasagiline—Discomfort—Prednisone—psoriasis	0.000118	0.000217	CcSEcCtD
Rasagiline—Mental disorder—Methotrexate—psoriasis	0.000118	0.000217	CcSEcCtD
Rasagiline—Malnutrition—Methotrexate—psoriasis	0.000117	0.000216	CcSEcCtD
Rasagiline—MAOB—Metabolism—CAT—psoriasis	0.000117	0.000812	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CRP—psoriasis	0.000117	0.00081	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—NFKB1—psoriasis	0.000116	0.00081	CbGpPWpGaD
Rasagiline—Hypersensitivity—Prednisolone—psoriasis	0.000116	0.000214	CcSEcCtD
Rasagiline—Dyspepsia—Betamethasone—psoriasis	0.000116	0.000213	CcSEcCtD
Rasagiline—Dyspepsia—Dexamethasone—psoriasis	0.000116	0.000213	CcSEcCtD
Rasagiline—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000116	0.000213	CcSEcCtD
Rasagiline—Urticaria—Triamcinolone—psoriasis	0.000115	0.000212	CcSEcCtD
Rasagiline—Dysgeusia—Methotrexate—psoriasis	0.000115	0.000212	CcSEcCtD
Rasagiline—Body temperature increased—Triamcinolone—psoriasis	0.000115	0.000211	CcSEcCtD
Rasagiline—Dizziness—Cyclosporine—psoriasis	0.000115	0.000211	CcSEcCtD
Rasagiline—Decreased appetite—Betamethasone—psoriasis	0.000114	0.000211	CcSEcCtD
Rasagiline—Decreased appetite—Dexamethasone—psoriasis	0.000114	0.000211	CcSEcCtD
Rasagiline—Infection—Prednisone—psoriasis	0.000114	0.00021	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000114	0.000209	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Betamethasone—psoriasis	0.000114	0.000209	CcSEcCtD
Rasagiline—Back pain—Methotrexate—psoriasis	0.000113	0.000209	CcSEcCtD
Rasagiline—Hypersensitivity—Hydrocortisone—psoriasis	0.000113	0.000209	CcSEcCtD
Rasagiline—Shock—Prednisone—psoriasis	0.000113	0.000208	CcSEcCtD
Rasagiline—Nervous system disorder—Prednisone—psoriasis	0.000112	0.000207	CcSEcCtD
Rasagiline—Dizziness—Mycophenolate mofetil—psoriasis	0.000112	0.000206	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-DRB1—psoriasis	0.000112	0.000776	CbGpPWpGaD
Rasagiline—Skin disorder—Prednisone—psoriasis	0.000111	0.000205	CcSEcCtD
Rasagiline—Hyperhidrosis—Prednisone—psoriasis	0.000111	0.000204	CcSEcCtD
Rasagiline—Asthenia—Hydrocortisone—psoriasis	0.00011	0.000203	CcSEcCtD
Rasagiline—Vomiting—Cyclosporine—psoriasis	0.00011	0.000203	CcSEcCtD
Rasagiline—Rash—Cyclosporine—psoriasis	0.000109	0.000201	CcSEcCtD
Rasagiline—Anorexia—Prednisone—psoriasis	0.000109	0.000201	CcSEcCtD
Rasagiline—Dermatitis—Cyclosporine—psoriasis	0.000109	0.000201	CcSEcCtD
Rasagiline—Pruritus—Hydrocortisone—psoriasis	0.000109	0.000201	CcSEcCtD
Rasagiline—Ill-defined disorder—Methotrexate—psoriasis	0.000109	0.000201	CcSEcCtD
Rasagiline—Headache—Cyclosporine—psoriasis	0.000108	0.0002	CcSEcCtD
Rasagiline—Anaemia—Methotrexate—psoriasis	0.000108	0.0002	CcSEcCtD
Rasagiline—Feeling abnormal—Dexamethasone—psoriasis	0.000108	0.0002	CcSEcCtD
Rasagiline—Feeling abnormal—Betamethasone—psoriasis	0.000108	0.0002	CcSEcCtD
Rasagiline—Gastrointestinal pain—Dexamethasone—psoriasis	0.000108	0.000198	CcSEcCtD
Rasagiline—Gastrointestinal pain—Betamethasone—psoriasis	0.000108	0.000198	CcSEcCtD
Rasagiline—Vomiting—Mycophenolate mofetil—psoriasis	0.000107	0.000198	CcSEcCtD
Rasagiline—BCL2—Immune System—ICAM1—psoriasis	0.000107	0.000745	CbGpPWpGaD
Rasagiline—Hypersensitivity—Triamcinolone—psoriasis	0.000107	0.000197	CcSEcCtD
Rasagiline—Rash—Mycophenolate mofetil—psoriasis	0.000107	0.000196	CcSEcCtD
Rasagiline—Dermatitis—Mycophenolate mofetil—psoriasis	0.000106	0.000196	CcSEcCtD
Rasagiline—BCL2—Immune System—NFKBIA—psoriasis	0.000106	0.000739	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NDUFA5—psoriasis	0.000106	0.000736	CbGpPWpGaD
Rasagiline—Headache—Mycophenolate mofetil—psoriasis	0.000106	0.000195	CcSEcCtD
Rasagiline—Malaise—Methotrexate—psoriasis	0.000106	0.000195	CcSEcCtD
Rasagiline—Vertigo—Methotrexate—psoriasis	0.000105	0.000194	CcSEcCtD
Rasagiline—Diarrhoea—Hydrocortisone—psoriasis	0.000105	0.000194	CcSEcCtD
Rasagiline—Leukopenia—Methotrexate—psoriasis	0.000105	0.000193	CcSEcCtD
Rasagiline—Urticaria—Betamethasone—psoriasis	0.000104	0.000193	CcSEcCtD
Rasagiline—Urticaria—Dexamethasone—psoriasis	0.000104	0.000193	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Prednisone—psoriasis	0.000104	0.000192	CcSEcCtD
Rasagiline—Dizziness—Prednisolone—psoriasis	0.000104	0.000192	CcSEcCtD
Rasagiline—Asthenia—Triamcinolone—psoriasis	0.000104	0.000192	CcSEcCtD
Rasagiline—Body temperature increased—Dexamethasone—psoriasis	0.000104	0.000192	CcSEcCtD
Rasagiline—Abdominal pain—Betamethasone—psoriasis	0.000104	0.000192	CcSEcCtD
Rasagiline—Abdominal pain—Dexamethasone—psoriasis	0.000104	0.000192	CcSEcCtD
Rasagiline—Body temperature increased—Betamethasone—psoriasis	0.000104	0.000192	CcSEcCtD
Rasagiline—Insomnia—Prednisone—psoriasis	0.000104	0.000191	CcSEcCtD
Rasagiline—Nausea—Cyclosporine—psoriasis	0.000103	0.00019	CcSEcCtD
Rasagiline—Paraesthesia—Prednisone—psoriasis	0.000103	0.000189	CcSEcCtD
Rasagiline—Pruritus—Triamcinolone—psoriasis	0.000103	0.000189	CcSEcCtD
Rasagiline—Cough—Methotrexate—psoriasis	0.000102	0.000189	CcSEcCtD
Rasagiline—Dizziness—Hydrocortisone—psoriasis	0.000102	0.000188	CcSEcCtD
Rasagiline—Convulsion—Methotrexate—psoriasis	0.000102	0.000187	CcSEcCtD
Rasagiline—Dyspepsia—Prednisone—psoriasis	0.000101	0.000186	CcSEcCtD
Rasagiline—Nausea—Mycophenolate mofetil—psoriasis	0.0001	0.000185	CcSEcCtD
Rasagiline—Chest pain—Methotrexate—psoriasis	9.98e-05	0.000184	CcSEcCtD
Rasagiline—Arthralgia—Methotrexate—psoriasis	9.98e-05	0.000184	CcSEcCtD
Rasagiline—Decreased appetite—Prednisone—psoriasis	9.95e-05	0.000183	CcSEcCtD
Rasagiline—Rash—Prednisolone—psoriasis	9.94e-05	0.000183	CcSEcCtD
Rasagiline—Dermatitis—Prednisolone—psoriasis	9.93e-05	0.000183	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	9.91e-05	0.000183	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.87e-05	0.000686	CbGpPWpGaD
Rasagiline—Headache—Prednisolone—psoriasis	9.87e-05	0.000182	CcSEcCtD
Rasagiline—Discomfort—Methotrexate—psoriasis	9.86e-05	0.000182	CcSEcCtD
Rasagiline—Constipation—Prednisone—psoriasis	9.79e-05	0.00018	CcSEcCtD
Rasagiline—Vomiting—Hydrocortisone—psoriasis	9.79e-05	0.00018	CcSEcCtD
Rasagiline—Rash—Hydrocortisone—psoriasis	9.7e-05	0.000179	CcSEcCtD
Rasagiline—Dermatitis—Hydrocortisone—psoriasis	9.69e-05	0.000179	CcSEcCtD
Rasagiline—Confusional state—Methotrexate—psoriasis	9.65e-05	0.000178	CcSEcCtD
Rasagiline—Headache—Hydrocortisone—psoriasis	9.64e-05	0.000178	CcSEcCtD
Rasagiline—Dizziness—Triamcinolone—psoriasis	9.58e-05	0.000177	CcSEcCtD
Rasagiline—Infection—Methotrexate—psoriasis	9.51e-05	0.000175	CcSEcCtD
Rasagiline—Feeling abnormal—Prednisone—psoriasis	9.44e-05	0.000174	CcSEcCtD
Rasagiline—Asthenia—Betamethasone—psoriasis	9.43e-05	0.000174	CcSEcCtD
Rasagiline—Asthenia—Dexamethasone—psoriasis	9.43e-05	0.000174	CcSEcCtD
Rasagiline—Nervous system disorder—Methotrexate—psoriasis	9.39e-05	0.000173	CcSEcCtD
Rasagiline—Gastrointestinal pain—Prednisone—psoriasis	9.36e-05	0.000173	CcSEcCtD
Rasagiline—Nausea—Prednisolone—psoriasis	9.36e-05	0.000172	CcSEcCtD
Rasagiline—Pruritus—Betamethasone—psoriasis	9.3e-05	0.000171	CcSEcCtD
Rasagiline—Pruritus—Dexamethasone—psoriasis	9.3e-05	0.000171	CcSEcCtD
Rasagiline—Skin disorder—Methotrexate—psoriasis	9.3e-05	0.000171	CcSEcCtD
Rasagiline—Hyperhidrosis—Methotrexate—psoriasis	9.25e-05	0.00017	CcSEcCtD
Rasagiline—Vomiting—Triamcinolone—psoriasis	9.21e-05	0.00017	CcSEcCtD
Rasagiline—Nausea—Hydrocortisone—psoriasis	9.14e-05	0.000168	CcSEcCtD
Rasagiline—Rash—Triamcinolone—psoriasis	9.14e-05	0.000168	CcSEcCtD
Rasagiline—Dermatitis—Triamcinolone—psoriasis	9.13e-05	0.000168	CcSEcCtD
Rasagiline—Anorexia—Methotrexate—psoriasis	9.12e-05	0.000168	CcSEcCtD
Rasagiline—Urticaria—Prednisone—psoriasis	9.1e-05	0.000168	CcSEcCtD
Rasagiline—MAOB—Metabolism—APOE—psoriasis	9.08e-05	0.000631	CbGpPWpGaD
Rasagiline—Headache—Triamcinolone—psoriasis	9.08e-05	0.000167	CcSEcCtD
Rasagiline—Body temperature increased—Prednisone—psoriasis	9.05e-05	0.000167	CcSEcCtD
Rasagiline—Abdominal pain—Prednisone—psoriasis	9.05e-05	0.000167	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—CYP2S1—psoriasis	9e-05	0.000626	CbGpPWpGaD
Rasagiline—Diarrhoea—Dexamethasone—psoriasis	9e-05	0.000166	CcSEcCtD
Rasagiline—Diarrhoea—Betamethasone—psoriasis	9e-05	0.000166	CcSEcCtD
Rasagiline—Hypotension—Methotrexate—psoriasis	8.94e-05	0.000165	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Methotrexate—psoriasis	8.72e-05	0.000161	CcSEcCtD
Rasagiline—BCL2—Immune System—TYK2—psoriasis	8.71e-05	0.000605	CbGpPWpGaD
Rasagiline—Dizziness—Dexamethasone—psoriasis	8.7e-05	0.00016	CcSEcCtD
Rasagiline—Dizziness—Betamethasone—psoriasis	8.7e-05	0.00016	CcSEcCtD
Rasagiline—Insomnia—Methotrexate—psoriasis	8.66e-05	0.00016	CcSEcCtD
Rasagiline—Nausea—Triamcinolone—psoriasis	8.61e-05	0.000159	CcSEcCtD
Rasagiline—Paraesthesia—Methotrexate—psoriasis	8.59e-05	0.000158	CcSEcCtD
Rasagiline—Dyspnoea—Methotrexate—psoriasis	8.53e-05	0.000157	CcSEcCtD
Rasagiline—Somnolence—Methotrexate—psoriasis	8.51e-05	0.000157	CcSEcCtD
Rasagiline—Hypersensitivity—Prednisone—psoriasis	8.44e-05	0.000155	CcSEcCtD
Rasagiline—Dyspepsia—Methotrexate—psoriasis	8.42e-05	0.000155	CcSEcCtD
Rasagiline—Vomiting—Dexamethasone—psoriasis	8.36e-05	0.000154	CcSEcCtD
Rasagiline—Vomiting—Betamethasone—psoriasis	8.36e-05	0.000154	CcSEcCtD
Rasagiline—Decreased appetite—Methotrexate—psoriasis	8.32e-05	0.000153	CcSEcCtD
Rasagiline—Rash—Betamethasone—psoriasis	8.29e-05	0.000153	CcSEcCtD
Rasagiline—Rash—Dexamethasone—psoriasis	8.29e-05	0.000153	CcSEcCtD
Rasagiline—Dermatitis—Betamethasone—psoriasis	8.28e-05	0.000153	CcSEcCtD
Rasagiline—Dermatitis—Dexamethasone—psoriasis	8.28e-05	0.000153	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Methotrexate—psoriasis	8.26e-05	0.000152	CcSEcCtD
Rasagiline—Headache—Dexamethasone—psoriasis	8.24e-05	0.000152	CcSEcCtD
Rasagiline—Headache—Betamethasone—psoriasis	8.24e-05	0.000152	CcSEcCtD
Rasagiline—Asthenia—Prednisone—psoriasis	8.22e-05	0.000151	CcSEcCtD
Rasagiline—BCL2—Immune System—IFNG—psoriasis	8.15e-05	0.000567	CbGpPWpGaD
Rasagiline—Pruritus—Prednisone—psoriasis	8.1e-05	0.000149	CcSEcCtD
Rasagiline—MAOB—Metabolism—PPARG—psoriasis	7.91e-05	0.00055	CbGpPWpGaD
Rasagiline—Feeling abnormal—Methotrexate—psoriasis	7.89e-05	0.000145	CcSEcCtD
Rasagiline—BCL2—Immune System—CD4—psoriasis	7.87e-05	0.000547	CbGpPWpGaD
Rasagiline—Diarrhoea—Prednisone—psoriasis	7.83e-05	0.000144	CcSEcCtD
Rasagiline—Gastrointestinal pain—Methotrexate—psoriasis	7.83e-05	0.000144	CcSEcCtD
Rasagiline—Nausea—Dexamethasone—psoriasis	7.81e-05	0.000144	CcSEcCtD
Rasagiline—Nausea—Betamethasone—psoriasis	7.81e-05	0.000144	CcSEcCtD
Rasagiline—Urticaria—Methotrexate—psoriasis	7.6e-05	0.00014	CcSEcCtD
Rasagiline—Dizziness—Prednisone—psoriasis	7.57e-05	0.00014	CcSEcCtD
Rasagiline—Abdominal pain—Methotrexate—psoriasis	7.57e-05	0.000139	CcSEcCtD
Rasagiline—Body temperature increased—Methotrexate—psoriasis	7.57e-05	0.000139	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—IL6—psoriasis	7.31e-05	0.000508	CbGpPWpGaD
Rasagiline—Vomiting—Prednisone—psoriasis	7.28e-05	0.000134	CcSEcCtD
Rasagiline—Rash—Prednisone—psoriasis	7.22e-05	0.000133	CcSEcCtD
Rasagiline—Dermatitis—Prednisone—psoriasis	7.21e-05	0.000133	CcSEcCtD
Rasagiline—Headache—Prednisone—psoriasis	7.17e-05	0.000132	CcSEcCtD
Rasagiline—Hypersensitivity—Methotrexate—psoriasis	7.05e-05	0.00013	CcSEcCtD
Rasagiline—BCL2—Immune System—JUN—psoriasis	7.05e-05	0.00049	CbGpPWpGaD
Rasagiline—Asthenia—Methotrexate—psoriasis	6.87e-05	0.000127	CcSEcCtD
Rasagiline—Nausea—Prednisone—psoriasis	6.8e-05	0.000125	CcSEcCtD
Rasagiline—BCL2—Immune System—NFKB1—psoriasis	6.78e-05	0.000472	CbGpPWpGaD
Rasagiline—Pruritus—Methotrexate—psoriasis	6.77e-05	0.000125	CcSEcCtD
Rasagiline—Diarrhoea—Methotrexate—psoriasis	6.55e-05	0.000121	CcSEcCtD
Rasagiline—Dizziness—Methotrexate—psoriasis	6.33e-05	0.000117	CcSEcCtD
Rasagiline—BCL2—Immune System—STAT3—psoriasis	6.1e-05	0.000424	CbGpPWpGaD
Rasagiline—Vomiting—Methotrexate—psoriasis	6.08e-05	0.000112	CcSEcCtD
Rasagiline—Rash—Methotrexate—psoriasis	6.03e-05	0.000111	CcSEcCtD
Rasagiline—Dermatitis—Methotrexate—psoriasis	6.03e-05	0.000111	CcSEcCtD
Rasagiline—Headache—Methotrexate—psoriasis	6e-05	0.00011	CcSEcCtD
Rasagiline—Nausea—Methotrexate—psoriasis	5.68e-05	0.000105	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.72e-05	0.000328	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CARM1—psoriasis	4.4e-05	0.000306	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6—psoriasis	4.26e-05	0.000296	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.11e-05	0.000286	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CAT—psoriasis	2.7e-05	0.000188	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—APOE—psoriasis	2.1e-05	0.000146	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPARG—psoriasis	1.83e-05	0.000127	CbGpPWpGaD
